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ABSTRACT  
Unfractionated heparin is the most commonly used anticoagulant for 
hemodialysis (HD).  It is well-known that heparin can cause immune-
mediated thrombocytopenia due to immunoglobulin antibody formation 
against the complex of platelet factor 4 (PF4) and heparin. Heparin may 
also contribute to HD-associated platelet activation, thrombocytopenia, 
and increased PF4 release from platelets during a heparin dialytic session. 
The present study was conducted to study the effect of unfraction heparin 
as anticoagulant in newly treatment hemodialysis patients. Material and 
method: A sample of 72 people were selected, 32 patients on dialysis for 
first time from unite of kidney dialysis. At the same time a group of 40 
randomly selected healthy adults to participate in the study as control. By 
Automated cell counter (sysmex X 21) platelets from all patients on 
dialysis before starting heparin and after one month later were estimated. 
Result: The mean value of platelets in patients after treated with heparin 
was significant lower (192.3 ± 20.7 ) × 109/l as compare before treated 
with heparin 203 ± 20.7  × 109/l  ( P = 0.001). Conclusion: From this study, 
heparin as anti-coagulant has effect on decrease platelets count but still 
patients have no thrombocytopenia platelets level ≥ 150 × 109/l. 




Unfractionated heparin (heparin) is the most commonly 
used anticoagulant for hemodialysis (HD)[1]. Heparin can 
cause serious adverse effects including heparin induced 
thrombocytopenia (HIT) which is a common serious and 
potentially life threat condition. 
Heparin may also contribute to HD-associated platelet 
activation, thrombocytopenia, and increased PF4 
release from platelets during a heparin dialytic session 
[2]. Typically, IgG isotype HIT antibodies develop after 5-
14 days of heparin exposure. The incidence of heparin-
induced thrombocytopenia (HIT) was estimated at 3.9% 
in newly treated hemodialysis patients[3]. Also, dialysis 
is often complicated by clotting of the dialysis lines 
and/or dialyzer due to hypercoagulation regardless of 
the etiology. When a diagnosis of HIT based on clinical 
symptoms of thrombocytopenia and immunoassay for 
PF4/heparin complex antibodies is employed, it 
remains unclear whether a few patients have HIT. An 
antigen-based immunoassay to detect the presence of 
antibodies in a patient’s circulation that binds to the 
PF4/heparin complex is highly sensitive but less specific.  
Two different types of HIT are recognized. The first, HIT 
type I also called heparin induced thrombocytopenia in 
the past, this form affect up to 10% of patients under 
treatment with heparin and is characterized by mild 
and transient asymptomatic thrombocytopenia (rarely 
less than 100 × 109 /l) that develops early usually 
within the first two days of starting heparin and 
disappears quickly once heparin is withdraw. 
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The second form of HIT, HIT type II, is immune 
mediated and associated with a risk of thrombosis. It 
has been proposed that the term HIT type I be changed 
to non- immune heparin associated thrombocytopenia 
and that the term HIT type II be changed to HIT to avoid 
confusion between the two syndrome. [4]     
MATERIAL AND METHODOLOGY 
Study design : A case control study was designed 
evaluate platelets count in patients on dialysis before 
starting heparin and after stopping heparin  and 
compared platelets count with healthy individual not 
using heparin. 
Ethical approval: Approval was granted from the 
Research and Ethics Committee of the faculty. Consent 
was gotten from all participated patients. 
Sample size and sampling method: A sample of 72, 32 
were on hemodialysis and 40 were healthy individual 
were included in the study and measure platelets count 
by automated cell counter for all. 
Inclusion criteria: patients on hemodialysis aged 15 
year and more were selected from unite of dialysis, 
most of them were  the first time for dialysis, control  
aged 20 and all had no history of any medical problem 
may affect platelets  count . 
Exclusion criteria: the study include healthy individual 
who use any drugs affect platelets count and haveing 
any previous disease affect platelet 
Methodology: Five ml of blood samples from all 
patients and controlled were collected by vein puncture 
in EDTA container. A whole blood specimen containing 
formed cellular elements, 20 µl of blood is diluted with 
a premeasured 1.9 ml volume of ammonium oxalate, 
sorensens phosphoate buffer, thimerosal, and purified 
water. Fresh capillary or anticoagulant whole blood is 
added to the diluents, which lyses erythrocytes but 
preserves platelets for 1:10 dilution of the blood [4]. The 
diluted specimen is added to a hemocytometer for 
manual enumeration of platelets in special 
circumstances. By Automated cell counter (sysmex X 
21) platelets from all patients on dialysis before starting 
heparin and one month later were estimated. 
Statistical analysis: Result are expressed as mean 
values ± SD. Data were analyzed by t test using. 
Significant difference was considered to exist at P value 
less than 0.05. 
RESULTS 
Total of 72 sample were included in this study, 40 
normal healthy persons were included in the study as 
control subject mean age (25.06 ±3.73) with a range 20-
50 year and they were clinically healthy and free of any 
serious illness. 
Thirty-two patients were selected from the unit of 
kidney dialysis from Al-wahda, Teaching Hospital, 
Derna, mean age (42.3±16.8) with a range (15-90) year. 
The mean value of platelet count in patients before 
starting heparin  203 × 109/l with standard deviation ± 
20.7 while mean value with standard deviation after 
one month  192.3 ± 20.7 × 109/l. The mean platelets 
count in healthy individual 267.09 with standard 
deviation 69.0 × 109/l. By applying unpaired t test, we 
found that, there were significantly decreased value of 
platelets count between patients before starting 
heparin and healthy individual P ≤ 0.01 as in table 1, 
and there was significant decrease in platelet before 
starting heparin and after one month of stopping it P≤ 
0.001 as in table 2.   








209.29 ± 57.4 267.09 ± 69 Mean ± SD 
≤ 0.01 P –value 
Table 2. Comparing Platelets count level × 109 /l in patients 
requiring hemodialysis before starting heparin and after 
stopping heparin 
After treatment Before 
treatment 
Parameters 
32 32 Number of 
patients 
192.3  ± 20.7 203.0 ± 20.7 Mean ± SD 
P ≤ 0.001 P- value 
DISCUSSION  
Heparin induced thrombocytopenia is the development 
of thrombocytopenia due to administration of the 
forms of anticoagulant (anti-blood clotting inhibitor) 
heparin. 
Unfractionated heparin is the most commonly used 
anticoagulant for hemodialysis[5] (HD). It is well-known 
that heparin can cause immune-mediated 
thrombocytopenia due to immunoglobulin antibody 
formation against the complex of platelet factor 4 (PF4) 
and heparin. Heparin may also contribute to HD-
associated platelet activation, thrombocytopenia, and 
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increased PF4 release from platelets during a heparin 
dialytic session[6]. Typically, IgG isotype HIT antibodies 
develop after 5- 14 days of heparin exposure. The 
incidence of heparin-induced thrombocytopenia (HIT) 
was estimated at 3.9% in newly treated hemodialysis 
patients[7]. Also, dialysis is often complicated by clotting 
of the dialysis lines and/or dialyzer due to 
hypercoagulation regardless of the etiology. When a 
diagnosis of HIT based on clinical symptoms of 
thrombocytopenia and immunoassay for PF4/heparin 
complex antibodies is employed, it remains unclear 
whether a few patients have HIT. 
Few reports on the frequency of HIT in dialysis patients 
are known, although heparin is employed as the most 
useful anticoagulant during dialysis. It was believed that 
the frequency of HIT would be low in a survey targeting 
to all dialytic patients including both acute and chronic 
stages[8]. Two surveys involving different subjects show 
quite different figures on the frequency of HIT. A 
relatively high frequency of 3.2% was reported for 
newly treated subjects receiving dialysis in three 
months[9], and a low rate frequency of 0.6% is described 
in chronic dialysis patients treated for over 3 
months[10,11]. Thus, the frequency of HIT in a dialysis 
population is different between newly treated and 
chronic maintained dialytic groups. HIT in the former 
shows a similar incidence to the heparin-sensitive 
group, and HIT in the later group is rarely identified as 
HIT or recurrence of HIT when a patient experiences 
changes in the immunological tolerance brought about 
by cardiovascular surgery, orthopedic surgery, and 
high-dose administration of erythropoietin with an 
adverse platelet-stimulating reaction. 
This study include all patients who were first time on 
dialysis (newly treated) and come to the unite monthly 
platelets count before starting heparin, in comparing 
with healthy individual was significantly lower, Mean ± 
SD (209 ± 57.4) as compare to healthy controls (267.09 
±  69) × 109/l P ≤ 0.001.  
At the same time platelets count level was significant 
decrease in patients after taking heparin (192.0 ± 20.75) 
as compare before start to take heparin (203.0 ± 20.7) × 
109 /l. 
heparin as anti-coagulant has effect on decrease 
platelets count but still patients have not 
thrombocytopenia platelets level ≥ 150 × 109/l. 
CONCLUSION 
Heparin induced non immune thrombocytopenia since 
with decreasing in platelets count there were no 
symptoms of thrombosis, it’s a benign form not 
associated with an increase risk of thrombosis, the 
mechanism of HIT type I is still unknown but it is likely 
to be non-immune, probably related to its platelet pro-
aggregating effect. 
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